US 12,338,229 B2
Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
Bert W. O'Malley, Houston, TX (US); David Michael Lonard, Pearland, TX (US); and Yongcheng Song, Pearland, TX (US)
Assigned to BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
Filed by BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
Filed on Jun. 5, 2023, as Appl. No. 18/205,630.
Application 18/205,630 is a continuation of application No. 17/030,924, filed on Sep. 24, 2020, granted, now 11,708,350.
Application 17/030,924 is a continuation of application No. 16/554,733, filed on Aug. 29, 2019, granted, now 10,875,841, issued on Dec. 29, 2020.
Claims priority of provisional application 62/825,358, filed on Mar. 28, 2019.
Claims priority of provisional application 62/724,281, filed on Aug. 29, 2018.
Prior Publication US 2023/0357200 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61P 9/10 (2006.01); C07D 401/08 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 9/10 (2018.01); C07D 401/08 (2013.01)] 13 Claims
 
1. A compound of the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10 are each independently selected from CR1 and N, wherein at least one of A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10 is N, and wherein each R1 is hydrogen, halogen, alkoxy, cyano, trifluoromethyl, or substituted or unsubstituted C1-6 alkyl; and
R2 is substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl, wherein R2 is not cyclopropyl.